Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kanwal Raghav

Showing results (51-60 of 102) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2020
Population-based Screening for <i>BRAF</i> <sup>V600E</sup> in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor PrognosisJenny E Chu, Benny Johnson, Laveniya Kugathasan, et al.
Clinical Colorectal Cancer|July 16, 2020
FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall SurvivalAlexandre A Jácome, Bryan Kee, David Fogelman, et al.
The Oncologist|March 23, 2026
A retrospective analysis of taxane-based chemotherapy in small bowel adenocarcinomaMir Lim, Nikhil Grandhi, Preksha Shah, et al.
The Oncologist|August 10, 2022
Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center ExperienceVictoria Serpas Higbie, Jane Rogers, Hyunsoo Hwang, et al.
Plos One|August 30, 2017
Clinical utility of circulating cell-free DNA in advanced colorectal cancerAllan A Lima Pereira, Maria Pia Morelli, Michael Overman, et al.
JCO Precision Oncology|September 11, 2020
Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal CancerBenny Johnson, Jonathan M Loree, Alexandre A Jacome, et al.
Nature Communications|November 25, 2024
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, et al.
Oncotarget|July 16, 2016
MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenonKanwal Raghav, Van Morris, Chad Tang, et al.
Langenbeck'S Archives of Surgery|February 28, 2023
Prognostic significance of acellular mucin in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal neoplasmsDerek J Erstad, Kristen A Robinson, Karen Beaty, et al.
Nature Communications|January 15, 2025
Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, et al.
Pageof 11

Showing results (51-60 of 102) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2020
Population-based Screening for <i>BRAF</i> <sup>V600E</sup> in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor PrognosisJenny E Chu, Benny Johnson, Laveniya Kugathasan, et al.
Clinical Colorectal Cancer|July 16, 2020
FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall SurvivalAlexandre A Jácome, Bryan Kee, David Fogelman, et al.
The Oncologist|March 23, 2026
A retrospective analysis of taxane-based chemotherapy in small bowel adenocarcinomaMir Lim, Nikhil Grandhi, Preksha Shah, et al.
The Oncologist|August 10, 2022
Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center ExperienceVictoria Serpas Higbie, Jane Rogers, Hyunsoo Hwang, et al.
Plos One|August 30, 2017
Clinical utility of circulating cell-free DNA in advanced colorectal cancerAllan A Lima Pereira, Maria Pia Morelli, Michael Overman, et al.
JCO Precision Oncology|September 11, 2020
Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal CancerBenny Johnson, Jonathan M Loree, Alexandre A Jacome, et al.
Nature Communications|November 25, 2024
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, et al.
Oncotarget|July 16, 2016
MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenonKanwal Raghav, Van Morris, Chad Tang, et al.
Langenbeck'S Archives of Surgery|February 28, 2023
Prognostic significance of acellular mucin in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal neoplasmsDerek J Erstad, Kristen A Robinson, Karen Beaty, et al.
Nature Communications|January 15, 2025
Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, et al.
Pageof 11